Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06444165
Status:
COMPLETED
Last Update Posted:
2024-07-10
First Post:
2024-05-31
Brief Title:
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the ease of use of the lebrikizumab pen Participants will use a practice pad to simulate administration of a dose Participants will complete the modified Subcutaneous Administration Assessment Questionnaire mSQAAQ following the simulated injection
This study involves one study visit
This study involves one study visit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2T-MC-KGBY | OTHER | Eli Lilly and Company | None |